Results from randomized controlled trials (RCTs) have raised concern that the cholesterol-lowering drug ezetimibe might increase the risk of cancer. We tested the hypothesis that genetic variation in NPC1L1, mimicking treatment with ezetimibe, was associated with an increased risk of cancer.

中文翻译：

---

利用遗传学探索降低胆固醇的药物依泽替米贝是否可能增加患癌症的风险

随机对照试验（RCT）的结果引起了人们的关注，即降低胆固醇的药物依泽替米贝可能会增加患癌症的风险。我们检验了以下假设：模仿ezetimibe治疗的NPC1L1的遗传变异与罹患癌症的风险增加相关。